EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis

Mol Cancer. 2010 Feb 9:9:32. doi: 10.1186/1476-4598-9-32.

Abstract

Background: About 30-50% of Hodgkin lymphomas (HLs) harbor the Epstein-Barr virus (EBV), but the impact of EBV infection on clinical outcomes has been unclear. EBV-encoded small RNAs (EBERs) are presented in all EBV-infected cells, but their functions are still less understood.

Results: EBER1 was transfected into two HL cell lines, KMH2 and L428, and microarrays were used to screen for EBER1-induced changes. We found that EBER1 suppressed p21cip1/waf1 transcription in HL cell lines. In addition, positive regulators of p21cip1/waf1 transcription, such as p53, EGR1, and STAT1, were decreased. Suppression of p21cip1/waf1 in the EBER1+ HL cell lines was associated with increased resistance to histone deacetylase inhibitors or proteasome inhibitors, drugs known to cause apoptosis by increasing p21cip1/waf1 levels. On biopsy specimens, EBV+ HLs had weaker expression of both p21cip1/waf1 and active caspase 3. Clinically, suppression of p21cip1/waf1 in EBV+ HLs was associated with a worse 2-year disease-free survival rate (45% for EBV+ HLs vs. 77% for EBV- HLs, p = 0.002).

Conclusion: Although the underlying mechanisms are still relatively unclear, EBER1 inhibits p21cip1/waf1 transcription and prevents apoptosis through down-regulation of p53, EGR1, and STAT1. The anti-apoptotic activity of EBER1 may be important in the rescue of Reed-Sternberg cells from drug-induced apoptosis and in the clinical behaviors of EBV+ HLs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects
  • Cell Cycle / drug effects
  • Cell Line, Tumor
  • Cyclin D2 / metabolism
  • Cyclin-Dependent Kinase Inhibitor p21 / genetics
  • Cyclin-Dependent Kinase Inhibitor p21 / metabolism*
  • Drug Resistance, Neoplasm / drug effects
  • Early Growth Response Protein 1 / genetics
  • Early Growth Response Protein 1 / metabolism
  • Gene Expression Regulation, Neoplastic / drug effects
  • Herpesvirus 4, Human / drug effects
  • Herpesvirus 4, Human / physiology*
  • Hodgkin Disease / diagnosis*
  • Hodgkin Disease / genetics
  • Hodgkin Disease / pathology
  • Hodgkin Disease / virology*
  • Humans
  • Hydroxamic Acids / pharmacology
  • Leupeptins / pharmacology
  • Models, Biological
  • Prognosis
  • RNA, Viral / metabolism
  • STAT1 Transcription Factor / genetics
  • STAT1 Transcription Factor / metabolism
  • Transcription, Genetic / drug effects
  • Tumor Suppressor Protein p53 / metabolism

Substances

  • Cyclin D2
  • Cyclin-Dependent Kinase Inhibitor p21
  • EGR1 protein, human
  • Early Growth Response Protein 1
  • Epstein-Barr virus encoded RNA 1
  • Hydroxamic Acids
  • Leupeptins
  • RNA, Viral
  • STAT1 Transcription Factor
  • STAT1 protein, human
  • Tumor Suppressor Protein p53
  • carbobenzoxy-leucyl-leucyl-norvalinal
  • trichostatin A